Can CAR-T cells free HIV patients from daily medication?
NCT ID NCT04648046
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether specially engineered immune cells (CAR-T cells) can control HIV in people who stop their regular antiretroviral drugs. 18 participants will receive a single infusion of their own modified cells, with some also getting a mild chemotherapy drug beforehand. After infusion, HIV medications are paused to see if the engineered cells can keep the virus in check. The main goals are safety and whether the virus stays suppressed for at least 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified immune cells (CAR-T cells) targeting HIV
What this could lead to
If successful, this could allow people with HIV to stop daily antiretroviral therapy while keeping the virus under control.
What could go wrong
This is a very early, small trial (18 people) focused on safety. The CAR-T cells may not persist or control HIV, and there are risks from the conditioning chemotherapy and potential side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, Davis
RECRUITINGSacramento, California, 95817, United States
Contact Email: •••••@•••••
Contact
-
Zuckerberg San Francisco General
RECRUITINGSan Francisco, California, 94110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact